中位随访30个月，美国罗马琳达研究报告3年局部控制和特定疾病存活率为74 ％和72 ％分别。
With a median follow-up of 30 months, Loma Linda researchers reported three-year local control and disease-specific survival rates of 74% and 72% respectively.
这张照片中，一个病人在美国加州罗马琳达大学医学中心接受治疗，在那里质子加速器全球首次专用于医疗环境。
In this photo, a patient receives treatment at Loma Linda University Medical Center in California, the world's first proton accelerator built specifically for a medical environment.
罗马罗素法庭的秘书是琳达·本比。
罗马罗素法庭的秘书是琳达·本比。
应用推荐